ASKG712
Phase 1Biologic
ASKG712 is one of 59 biologic programs targeting Diabetic Macular Edema. It is currently in Phase 1.
2
Indications
2
Total Trials
2
Active Trials
58
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
43 competitors in Age-Related Macular Degeneration
#DrugCompanyPhaseTrials
1Eylea
RegeneronApproved
Plavix
SanofiApproved
Zometa
PfizerApproved
Bayer Aspirin
BayerApproved
Tecfidera
BiogenApproved
Visudyne
BBausch Health Americas, Inc.
Approved
Bendopa
MMerz North America, Inc.
Approved
Lodosyn
LLaTonya J. Hickson
Approved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ASKG712. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- AAskGene Pharma, Inc.